Pharmaceutical

JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Jul 9, 2025 - 06:00
JCR Pharma and Alexion partner on JUST-AAV gene therapy platform
JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.
Read the original article

Tags:

Previous Article

Microbiome Cell-Free RNA Differentiates Colorectal Cancer

Next Article

CTO East Coast 2025: Navigating shifting regulatory environment hinges on close ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments

Sanofi-backed Agomab raises $89m to advance fibrotic di...

Oct 26, 2024

STAT+: New insights into how tumor cells hijack brain plasticity to drive cancer

STAT+: New insights into how tumor cells hijack brain p...

Nov 1, 2023

STAT+: Alnylam reports growth in sales of rare disease treatments

STAT+: Alnylam reports growth in sales of rare disease ...

Aug 3, 2023